Table 3. SABA contribution to sold pMDI and DPI doses and associated carbon footprint in Sweden and in the UK in 2021*.
| Number of sold doses (million)† | Carbon footprint (kt CO2e) | Carbon footprint/100 000 population (kt CO2e) | |
|---|---|---|---|
| UK, 2021‡ | |||
| SABA (pMDI+DPI)§ | 6419 | 774 | |
| SABA (pMDI) | 6168 | 771 | 1.150 |
| SABA (DPI) | 250 | 3 | 0.004 |
| Total (pMDI+DPI sales) | 11 174 | ||
| Proportion SABA/national inhaler sales (%) | 57% | ||
| Sweden, 2021‡ | |||
| SABA (pMDI+DPI)§ | 236 | 11 | |
| SABA (pMDI) | 72 | 9 | 0.086 |
| SABA (DPI) | 164 | 2 | 0.016 |
| Total (pMDI+DPI sales) | 1260 | ||
| Proportion SABA/national inhaler sales (%) | 18% |
*
Based on IQVIA MIDAS Quarterly sales data for the year 2021, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.
†
Numbers reflect rounding.
‡
Soft mist inhaler and nebuliser sales are not included in the analysis.
§
The SABA molecules considered included salbutamol, fenoterol and terbutaline.
CO2e, carbon dioxide equivalents; DPI, dry powder inhaler; kt, metric kilotons; pMDI, pressurised metered dose inhaler; SABA, short-acting beta-2 agonist.